Results 211 to 220 of about 392,833 (299)

“It's the Exact Same Treatment … Except Only 5 Min Away”: A RE‐AIM Evaluation of a Speech‐Language Pathology Shared‐Care Model for Rural Patients With Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Background Challenges accessing post‐treatment speech‐language pathology (SLP) services can add to treatment burden for rural patients with head and neck cancer (HNC). Hence, the aim of this study was to evaluate a shared‐care SLP service designed to support local SLP access for patients with HNC, using the RE‐AIM framework.
Corey Patterson, Elizabeth C. Ward, Rebecca L. Packer, Jasmine Foley, Laurelie R. Wishart, Clare L. Burns, Sally Pether, Wendy Comben   +7 more
wiley   +1 more source

Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies. [PDF]

Am J Clin Dermatol
Senna M, Soung J, Figueras I, King B, Kinoshita-Ise M, Hanna S, Wu W, Wajsbrot D, Woodworth D, Wolk R, Chaudhry A, Lejeune A, Tran H.   +12 more
europepmc   +1 more source

Poor Diet and Oral Cavity Cancer Risk in Smoking and Non‐Smoking Men and Women: An Analysis of Three US Cohorts

Head &Neck, EarlyView.
ABSTRACT Introduction Oral cavity cancer (OCC) incidence is rising among non‐smokers and younger individuals without traditional risk factors. While carcinogenic exposures such as tobacco and alcohol are well studied, the association between unhealthy dietary patterns and OCC has been minimally explored.
Mateo Useche, Luis Gomez‐Castillo, Kara Cushing‐Haugen, Rocco Ferrandino, Neal Futran, Emily Marchiano, Cristina P. Rodriguez, Holly R. Harris, Brittany Barber   +8 more
wiley   +1 more source

Less is more? Dose reduction of biologics in psoriasis. [PDF]

J Eur Acad Dermatol Venereol
Papara C, Gyulai R.
europepmc   +1 more source

Fluorescence‐Guided Detection of Perineural and Bony Invasion With Margin Correlation in Gingival Squamous Cell Carcinoma Using Panitumumab‐IRDye800

Head &Neck, EarlyView.
ABSTRACT Background Near‐infrared (NIR) fluorescence‐guided surgery using EGFR‐targeted tracers (e.g., panitumumab‐IRDye800CW) can provide real‐time visualization of tumors and margins in Head and Neck Squamous Cell Carcinoma. Prior studies have demonstrated its safety and potential to improve intraoperative decision‐making and margin assessment ...
Makenna Brown, Mabrooka Kazi, Hidenori Tanaka, Brandee Brown, Mitra Mehrad, Sarah Rohde, Eben Rosenthal, Kyle Mannion   +7 more
wiley   +1 more source

Editor's Highlights-September 2026. [PDF]

Int J Dermatol
Kemény L.
europepmc   +1 more source

Safe Omission of Postoperative Neck Irradiation in Selected pN0 Patients With Locally Advanced Oral Cavity Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background Postoperative radiotherapy is the standard treatment for locally advanced oral squamous cell carcinoma (OSCC); however, the indication for neck irradiation (NI) in pN0 patients remains debatable. We evaluated whether the omission of NI compromises outcomes in pT3–T4 pN0 patients treated with adequate neck dissection (ND).
Mathilde Mirallié, Anouchka Modesto, Marie Pajiep, Sébastien Vergez, Jérôme Sarini, Lucie Piram, Céline Dalmasso, Benjamin Vairel, Emilien Chabrillac, Agnès Dupret‐Bories   +9 more
wiley   +1 more source

The Role of General Practitioners in Actinic Keratosis Management in Europe: A Dermato-Oncologists Initiative. [PDF]

J Clin Med
Ulrich C, Heppt MV, Argenziano G, Fargnoli MC, Ferrándiz-Pulido C, Jouary T, Lallas A, Martins C, Mosterd K, Saiag P, Bégeault N, Crespo-Cruz A.   +11 more
europepmc   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source